Pharmaceuticals

Sandoz Erelzi™ (etanercept) Receives Positive Reimbursement Recommendation from Common Drug Review for Treatment of Multiple Inflammatory Diseases

No comments
Sandoz Erelzi™ (etanercept) Receives Positive Reimbursement Recommendation from Common Drug Review for Treatment of Multiple Inflammatory Diseases

Sandoz, a Novartis division, recently announced that The Canadian Drug Expert Committee (CDEC) as part of the Common Drug Review (CDR) process has issued a positive drug reimbursement recommendation for Erelzi (etanercept). Health Canada granted Erelzi a Notice of Compliance in April 2017.

iData ResearchSandoz Erelzi™ (etanercept) Receives Positive Reimbursement Recommendation from Common Drug Review for Treatment of Multiple Inflammatory Diseases
read more